Zydus MedTech has partnered with Brazil-based Braile Biomedica to commercialize innovative TAVI technology across Europe, ...

A U.S. District Court recently ruled against Zydus and Lupin, finding Astellas's patent for Myrbetriq was not invalid. Both ...

The litigation was initiated by Astellas Pharma against Zydus Lifesciences concerning the validity of the ‘780 patent’, which ...

Ahmedabad: Zydus Lifesciences Limited has announced the execution of undertakings from 7 shareholders to tender 2,236,911 ...

HDFC Balanced Advantage Fund, Indias largest mutual fund scheme based on assets managed, added five new stocks in the portfolio in March, which include Trent, Varun Beverages, Alkem Laboratories, ...

Following the announcement of its envisaged tender offer on March 11, 2025, Zydus Lifesciences Limited announces the ...

The NSE Nifty 50 closed 0.47% higher at 23,437.2, while the BSE Sensex ended 0.4% up at 77,044.29 on Wednesday.

Lupin Ltd. and Zydus Lifesciences Ltd. shares fell sharply after a US court upheld Astellas Pharma’s patent on Myrbetriq, ...

Astellas Pharma Inc. defeated two generic-drug makers’ key invalidity defenses over a patent for Myrbetriq ER in a long-running clash over copycat versions of the overactive-bladder treatment. The ...

Indian shares rose for a third straight session on Wednesday, boosted by banks and as investors shrugged off global trade war ...